

UPDATE OF THE EARLY DEMAND MAP FOR THE PUBLIC INNOVATION PURCHASE OF THE MedeA PROJECT (PUBLISHED IN APRIL 2019).

NOTE: Corresponds to Old Challenges 2 and 3 in the Initial Early Demand Map (April 2019).

CHALLENGE 2: DEVELOPMENT OF SYSTEMS FOR PHARMACOGENETIC ANALYSIS		[SiGEN]
NEED	DESCRIPTION	PROCEDURE TO FOLLOW
<p>It is required to generate a database of genetic biomarkers, and if possible of metabolic phenotypes based on the determination of drugs, endobiotics and/or their metabolites, according to the requirements approved by the AEMPS/EMA, or whose analysis is recommended by specialized institutions at international level, so that:</p> <ul style="list-style-type: none"> • Provide information prior to the prescription of drugs, increasing the knowledge of the efficacy and/or possible toxicity of the pharmacological treatment according to the genetic endowment of the patient. • Increase the useful information analyzed to improve the predictive ability of response to drug treatment. • Decrease the response time when selecting the best treatment for the patient, also predicting the variability in the response to pharmacological treatment, and/or adverse effects. • Reduce the waiting time to achieve an effective response to a treatment, as well as the number of tests to be performed to obtain a correct drug choice and dosage. • Avoid visits and/or excessive use of post-prescription health care due to ineffective, inefficient or toxic treatment. • Lower the costs of implementation by obtaining information from several genes or genetic variations in a single analysis, as well as information from several drugs (if applicable) and/or other analytical biomarkers in a single analysis. 	<p>Development of a system for the evaluation of interindividual differences in drug response through laboratory analysis (SiGEN), presenting an innovative solution for the study of polymorphisms of pharmacogenetic relevance, as well as for the analytical determination of drugs and endogenous compounds (endobiotics) and their metabolites in biological matrices for application to clinical routine, connectable with the Personalized Prescription System (PoPS), developed in L.I.</p> <p>SiGEN Development</p> <p>Corresponds to Old Challenges 2 and 3 in the Initial Early Demand Map (April 2019).</p>	<p>Innovative Public Procurement / Innovation Partnership</p>

Budget available Challenge 2: **1,407,003 €.**

Maximum budget to be awarded per company in Phase I (VAT included): **938.001,91 €.**